Evaxion A/S EVAX
At closeNov 10, 2026, 4:14 PM EST
After hours · Nov 10, 4:14 PM ET
- YTD
- -40.04%
- 1 year
- -55.17%
- Market cap
- 26.38M
- Revenue (ttm)
- 3.29M
- EPS (ttm)
- -1.00
- Shares out
- 5.87M
- Forward P/E
- -0.72
- YTD return
- -40.04%
- 1-year return
- -55.17%
- Volume
- 92.21K
- Avg volume
- 240.74K
- Open
- 2.80
- Previous close
- 2.75
- Day's range
- 2.70 – 3.01
- 52-week range
- 2.67 – 6.92
- Beta
- -0.23
- Price target
- 11.56 (+304.3%)
- Earnings date
- Aug 14, 2024
5D -0.04 (-1.31%)
Key statistics
- Enterprise value
- 46.26M
- PEG ratio
- 0.00
- Price / sales
- 1.62
- Price / book
- 69.82
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 4.58M
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.74%
- 50-day average
- 1.95
- 200-day average
- 2.95
Analyst view
- Target (low)
- 7.00
- Target (mean)
- 11.56
- Target (high)
- 18.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | -0.12 | -0.04 | +0.08 | +66.67% |
| Aug 14, 2024 | Jun 1, 2024 | 0.02 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.02 | -0.12 | -0.14 | -700.00% |
| May 28, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 28, 2024 | Mar 1, 2024 | 0.00 | 0.03 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | 0.00 | -0.16 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Evaxion A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- evaxion-biotech.com
News
Evaxion A/S Submits Amendment To Its Registration Statement On Form F-1 Regarding 2025 Debt Settlement Agreement With The European Investment Bank With SEC 
Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement 
Evaxion Announces Data From Its Phase 2 Study Of EVX- In Participants With Advanced Melanoma Demonstrates Induced Immune Responses, Underlines Predictive Performance 
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01 
Recursion Pharmaceuticals (NASDAQ:RXRX) vs. Evaxion A/S (NASDAQ:EVAX) Financial Analysis - Evaxion To Demonstrate New Data For EVX-04 Vaccine At American Society Of Hematology Annual Meeting
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting 
Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting 
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution 
Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript
Your note
Sign in to keep a note on EVAX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.23% | 483,000 | 438.42K | Sep 29, 2024 |
| Invst, LLC | 0.74% | 43,200 | 39.21K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.25% | 14,825 | 13.46K | Sep 29, 2024 |
| Beacon Capital Management, LLC | 0.08% | 4,863 | 4.41K | Sep 29, 2024 |
| Blackrock Inc. | 0.03% | 1,512 | 1.37K | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.01% | 780 | 708 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 3,348 | 3.04K | Oct 30, 2024 |